Vericel (NASDAQ:VCEL) versus Surrozen (NASDAQ:SRZN) Financial Review

Vericel (NASDAQ:VCELGet Free Report) and Surrozen (NASDAQ:SRZNGet Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Profitability

This table compares Vericel and Surrozen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vericel 1.56% 1.48% 0.96%
Surrozen N/A -120.51% -54.68%

Insider and Institutional Ownership

66.6% of Surrozen shares are owned by institutional investors. 5.2% of Vericel shares are owned by company insiders. Comparatively, 43.5% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Vericel and Surrozen”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vericel $226.84 million 12.47 -$3.18 million $0.06 955.17
Surrozen $10.00 million 3.98 -$43.04 million N/A N/A

Vericel has higher revenue and earnings than Surrozen.

Volatility & Risk

Vericel has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Vericel and Surrozen, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel 0 0 6 1 3.14
Surrozen 0 0 0 0 0.00

Vericel presently has a consensus target price of $61.14, suggesting a potential upside of 6.69%. Given Vericel’s stronger consensus rating and higher possible upside, research analysts plainly believe Vericel is more favorable than Surrozen.

Summary

Vericel beats Surrozen on 11 of the 13 factors compared between the two stocks.

About Vericel

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

About Surrozen

(Get Free Report)

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.